Jazz Pharma Q3 rev $1.13B (+7%), GAAP EPS $4.08, adj. EPS $8.13; FY25 rev guid narrowed

Jazz Pharmaceuticals plc

2025-Q3 EPS reported -$9.18 revenue$3,069,660,000

Total revenues $1.126B (+7% YoY); GAAP net income $251M, non-GAAP adj. net income $501M.
Epidiolex sales grew 20% to $302.6M; Xywav sales grew 11% to $431.4M; Modeyso launch contributed $11.0M.
Zepzelca + atezolizumab combo approved for 1L maintenance ES-SCLC; NCCN inclusion.
Saniona licensing agreement for SAN2355, a Kv7.2/7.3 activator for epilepsy and other indications.
FY2025 total revenue guidance narrowed to $4.175-$4.275B from $4.150-$4.300B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.